Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aclacinomycin A (Aclarubicin) hydrochloride is a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | 待询 | 待询 | ||
10 mg | 待询 | 待询 | ||
25 mg | 待询 | 待询 | ||
50 mg | 待询 | 待询 | ||
100 mg | 待询 | 待询 | ||
200 mg | 待询 | 待询 | ||
1 mL * 10 mM (in DMSO) | 待询 | 待询 |
产品描述 | Aclacinomycin A (Aclarubicin) hydrochloride is a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II. |
体外活性 | Aclacinomycin A could efficiently enter living cells and emit fluorescence in situ. Aclacinomycin A (10 μM for 15 min) is sufficient for clear detection of fluorescence in most of the cultured cells. Aclacinomycin A treatment (10 μM for 15 min) results in approximately 20% dead (or nearly dead) cells [1]. Aclacinomycin A effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from an SMN2 minigene in the motor neuron cell line NSC34 [2]. |
体内活性 | Aclacinomycin A is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD50 (76.5 mg/kg) is about twice the iv LD50 (35.6 mg/kg) in mice. Aclacinomycin A (0.75-6 mg/kg, i.p daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model [4]. |
动物实验 | Animal Model: DBA/2, CDF1 (BALB/c×DBA/2) mice with Leukemia P-388. Dosage: 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. Administration: Intraperitoneal administration daily for 10 days starting 3 hr after transplantation. Result: Inhibited tumor growth [4]. |
别名 | 盐酸阿柔比星, Aclarubicin hydrochloride |
分子量 | 848.33 |
分子式 | C42H54ClNO15 |
CAS No. | 75443-99-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (147.35 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.1788 mL | 5.8939 mL | 11.7879 mL | 29.4697 mL |
5 mM | 0.2358 mL | 1.1788 mL | 2.3576 mL | 5.8939 mL | |
10 mM | 0.1179 mL | 0.5894 mL | 1.1788 mL | 2.947 mL | |
20 mM | 0.0589 mL | 0.2947 mL | 0.5894 mL | 1.4735 mL | |
50 mM | 0.0236 mL | 0.1179 mL | 0.2358 mL | 0.5894 mL | |
100 mM | 0.0118 mL | 0.0589 mL | 0.1179 mL | 0.2947 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Aclacinomycin A hydrochloride 75443-99-1 Proteases/Proteasome Ubiquitination Proteasome Aclacinomycin A Hydrochloride Aclarubicin Hydrochloride 盐酸阿柔比星 Aclarubicin hydrochloride Inhibitor inhibitor inhibit